Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 391 to 400 of 623 total matches.
In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
failure with reduced
ejection fraction (HFrEF).1 The indication has now
been expanded to include ...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga – AstraZeneca) was
approved by the FDA in 2020 to reduce the risk of
cardiovascular death and hospitalization for heart
failure (HF) in adults with heart failure with reduced
ejection fraction (HFrEF). The indication has now
been expanded to include a reduction in the risk
of urgent HF visits and use in adults with any left
ventricular ejection fraction (LVEF).
Med Lett Drugs Ther. 2023 Jun 26;65(1679):101-2 doi:10.58347/tml.2023.1679c | Show Introduction Hide Introduction
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
for
cardiovascular disease.1
MECHANISM OF ACTION — Inflammation is thought
to play an important role ...
Colchicine (Colcrys, and others), which has been
available in the US for decades for prophylaxis
and treatment of gout flares and other indications
in oral formulations that contain 0.6 mg of the
drug, has now been approved in 0.5-mg tablets as
Lodoco (Agepha) to reduce the risk of myocardial
infarction (MI), stroke, coronary revascularization,
and cardiovascular death in adults with established
atherosclerotic disease or multiple risk factors for
cardiovascular disease.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):156-7 doi:10.58347/tml.2023.1686b | Show Introduction Hide Introduction
In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020 (Issue 1610)
to be approved for this
indication; Entocort EC, an ileal-release formulation,
was the first.1 A third oral ...
An oral extended-release formulation of the corticosteroid
budesonide (Ortikos – Ferring) is now available
for once-daily treatment of mild to moderate active
Crohn's disease of the ileum and/or ascending colon in
patients ≥8 years old and for maintenance of remission
for up to 3 months in adults. Ortikos is the second oral
formulation of budesonide to be approved for this
indication; Entocort EC, an ileal-release formulation,
was the first. A third oral formulation of budesonide
(Uceris) is approved for induction of remission in
patients with mild to moderate active ulcerative...
Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis (online only)
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
– Dupixent (Sanofi/Regeneron) 200 mg/1.14 mL, 300 mg/2 mL prefilled pens, syringes IL-4 and IL-13 inhibitor ...
View the Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis
Med Lett Drugs Ther. 2025 Feb 17;67(1722):e1 doi:10.58347/tml.2025.1722f | Show Introduction Hide Introduction
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
90 mcg/inh
90 mcg/inh
0.63, 1.25, 2.5 mg/3 mL soln
HFA MDI (200 inh/unit)
HFA MDI (60, 200 inh ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7 doi:10.58347/tml.2024.1710b | Show Introduction Hide Introduction
Etrasimod (Velsipity) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
Etrasimod (Velsipity) for Ulcerative Colitis
The oral sphingosine 1-phosphate (S1P) receptor ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be approved
in the US for this indication; ozanimod (Zeposia) was
the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9 doi:10.58347/tml.2023.1690b | Show Introduction Hide Introduction
IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
with reduced quality of life and increased
hospitalization and mortality.1 Injectafer is the first
IV iron ...
Ferric carboxymaltose (Injectafer – American
Regent) is now FDA-approved for IV treatment of iron
deficiency in adults with New York Heart Association
(NYHA) class II/III heart failure to improve exercise
capacity. Iron deficiency is present in approximately
30% of patients with heart failure; it has been
associated with reduced quality of life and increased
hospitalization and mortality. Injectafer is the first
IV iron preparation to be approved for this indication.
It was previously approved for treatment of iron
deficiency anemia in children and adults.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):22-4 doi:10.58347/tml.2024.1695d | Show Introduction Hide Introduction
Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder (online only)
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
and a female to male
ratio of 4:1. It is characterized by early onset (within
3 months of birth), multiple ...
The FDA has approved ganaxolone (Ztalmy – Marinus)
for oral treatment of seizures associated with cyclin-dependent
kinase-like 5 (CDKL5) deficiency disorder
in patients ≥2 years old. It is the first drug to be
approved in the US for this indication.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):e139-40 doi:10.58347/tml.2024.1709g | Show Introduction Hide Introduction
Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria (online only)
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
(estimated
prevalence 38 cases per 1,000,000 persons) caused
by a severe deficiency in the complement ...
The FDA has approved the complement factor B
inhibitor iptacopan (Fabhalta – Novartis) for
treatment of paroxysmal nocturnal hemoglobinuria
(PNH) in adults. Iptacopan is the first oral drug to
be approved in the US for this indication. Three
parenterally administered drugs, the complement
C5 inhibitors eculizumab (Soliris) and ravulizumab
(Ultomiris) and the complement C3 inhibitor
pegcetacoplan (Empaveli), are also approved for
treatment of PNH.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e171-3 doi:10.58347/tml.2024.1712e | Show Introduction Hide Introduction
Guselkumab (Tremfya) — An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025 (Issue 1730)
earlier for treatment of ulcerative colitis (UC),
plaque psoriasis, and psoriatic arthritis.1 The IL-23 ...
The injectable interleukin (IL)-23 antagonist
guselkumab (Tremfya – Janssen Biotech) has now
been approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults; it was
approved earlier for treatment of ulcerative colitis (UC), plaque psoriasis, and psoriatic arthritis. The IL-23
antagonists risankizumab (Skyrizi) and mirikizumab
(Omvoh) and the IL-12/23 antagonist ustekinumab
(Stelara, and biosimilars) are also approved for
treatment of CD.
Med Lett Drugs Ther. 2025 Jun 9;67(1730):92-4 doi:10.58347/tml.2025.1730c | Show Introduction Hide Introduction